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Eight rifampin resistant streptococci of the mitis group were identified at the 1 
species level by using a concatenated 16S rDNA-sodA-rpoB-hlpA sequence. 2 
Characterization of their rpoB alleles showed single amino acid changes involved in 3 
rifampin resistance. Comparison of RpoB sequences from pneumococcal recombinant 4 
isolates, viridans isolates and type strains revealed a species-specific amino acid 5 
signature, which allowed ascertaining that recombinant RpoBs were originated in 6 
genetic interchanges with Streptococcus mitis and Streptococcus oralis. 7 
 3 
Viridans streptococci (VS) form part of the microbiota of the oropharynx, and the 1 
gastrointestinal and female genital tracts (13, 37). However, they cause endocarditis in 2 
native valves, and pneumonia in neutropenic cancer patients (7, 8, 43).  By their 16S 3 
ribosomal DNA (rDNA) sequences, VS can be classified into five groups: mutans, 4 
salivarius, anginosus, sanguinis and mitis (18). Species of the mitis group (SMG) includes 5 
Streptococcus mitis, Streptococcus sanguinis, Streptococcus parasanginis, Streptococcus 6 
gordonii, Streptococcus oralis, Streptococcus cristatus, Streptococcus infantis, 7 
Streptococcus peroris, Streptococcus pneumoniae, and Streptococcus pseudopneumoniae. 8 
Clinical features, together with their optochin susceptibility and bile solubility distinguish 9 
S. pneumoniae from other SMG species (27, 30, 39) although optochin susceptible VS have 10 
been found (6, 31). 11 
SMG isolated from blood cultures of cancer patients are commonly resistant to 12 
antibiotics (2, 16, 21, 22, 25, 42)  and  constitute a reservoir of resistance by acting as 13 
donors in the horizontal transfer of DNA to pneumococci, as observed for penicillin and 14 
fluoroquinolones (5, 17, 35, 38, 40). Rifampin is used in the treatment of tuberculosis and 15 
in meningitis caused by multiresistant pneumococcal strains, combined with either ß-16 
lactams or vancomycin (9, 33, 36). Rifampin binds to the DNA-dependent RNA 17 
polymerase (RpoB) inhibiting its function (10), which is essential for bacterial growth (15, 18 
26).  Resistance changes have been identified in four conserved regions (N, I, II and III) of 19 
RpoB in several bacteria (3, 4, 14, 24, 34). This resistance in S. pneumoniae is due to 20 
spontaneous mutations and it has been suggested to be also acquired by recombination with 21 
SMG species (19). In this study we have characterized rifampin-resistant SMG isolates, 22 
complementing the unique study of S. mitis (1), to ascertain the origin of the recombinant 23 
rpoB genes found in S. pneumoniae isolates.  24 
 4 
 Identification of viridans streptococci isolates to the species level. Among 1,272 VS 1 
isolates collected from adult patients at Hospital de Bellvitge (Barcelona) during ten years 2 
(1998-2007), 10 (0.79%) were rifampin-resistant as determined by broth microdilution and 3 
agar dilution (11, 12). Eight of them with high resistance level (MIC≥ 32µg/ml) were 4 
available for this study (Table 1). Although one VS isolate per patient was recovered, 5 
isolate 113 collected from patient 3 also yielded a rifampin-resistant S. anginosus isolate 6 
(113A) that was used for sequence comparisons. The global incidence of rifampin 7 
resistance observed in this study was similar to that found in Spain for S. pneumoniae 8 
(0.70%) (19), although a higher rate (3%) has been found  in SMG isolated from 9 
hematologic cancer patients (1).   10 
 The 8 VS isolates were identified by phenotypic (39) and  molecular methods. We used 11 
concatenated 16S rDNA-sodA-rpoB-hlpA sequences made with partial 16S rDNA, rpoB 12 
and sodA (1,198, 344, and 324-bp, respectively) and full hlpA (276-bp). To amplify 16S 13 
rDNA and hlpA we used the following primers: 16SDNAF1 (5’-14 
GAGTTGCGAACGGGTGAGT-3’) and 16SDNAR1 (5’-AGCGATTCCGACTTCAT-3’); 15 
huATG (5’-ATGGCAAACAAACAAGATT-3’) and huTAA (5’-16 
TTATTTAACAGCGTCTTTAAGAGC-3’). Partial sodA and rpoB were amplified and 17 
sequenced as described (28, 19). These genes were selected for their polymorphism among 18 
streptococci, and because they have been used as part of the ddl-gdh-rpoB-sodA sequence 19 
to differentiate SMG isolates (29). We assumed that hlpA, (coding the histone-like DNA 20 
binding protein HU) would improve our concatenated sequence discrimination capacity 21 
since HU, as an architectural cofactor, may require different DNA binding geometries (41), 22 
and probably sequence specificity. Clustering (bootstrap values ≥ 92%) in a phylogenetic 23 
 5 
tree of the 2,142-bp 16S rDNA-sodA-rpoB-hlpA sequences of the eight isolates and type 1 
strains allowed species identification (Fig. 1, Table 1). Among the six clusters observed 2 
(plus the out-group), all except S. pneumoniae/ S. pseudopneumoniae and S. sanguinis/ S. 3 
gordonii formed species-specific groups.  4 
 The within-group sequence diversity (mean ± standard deviation) for S. pneumoniae/ S. 5 
pseudopneumoniae (0.4% ± 0.1%), S. mitis (1.2% ± 0.3%), and  S. oralis (2.0% ± 0.5%) 6 
clusters, reflected low sequence diversity. Our S. pneumoniae/ S. pseudopneumoniae value 7 
was nearly half to that obtained using the ddl-gdh-rpoB-sodA concatenates (29) and for S. 8 
mitis, it was 4-to-5 fold lower than the value obtained by MLST (20, 23). Additionally, S. 9 
pneumoniae/ S. pseudopneumoniae, S. mitis, and S. oralis clusters were clearly separated, 10 
as their genetic distances to the node formed with the branch of  S. pneumoniae / S. 11 
pseudopneumoniae were: 1.1% ± 0.7%, 1.9% ± 0.0%, and 3.2% ± 0.4% (mean ± SD), 12 
which are statistically significant (p< 0.0001).  13 
 Determination of mutations involved in rifampin resistance. RpoB regions L42-14 
V175 and Q464-T702 were sequenced as described (19) and compared. Changes were 15 
found in the Q464- T702 region (Table 1 and Fig. 2). Among them, only H499N had been 16 
described in rifampin resistant in SMG (1), while the rest, with the exception of S504F  17 
(isolate 395),  had been involved in resistance in S. pneumoniae (19), To test its role in 18 
resistance, transformation of S. pneumoniae R6 with the Q464-T700 fragment carrying 19 
S504F was performed as described previously (32). The transformant had the same 20 
rifampin MIC of isolate 395 showing that this change was indeed involved in resistance. 21 
Additional changes in cluster III, which were present in both susceptible and resistant 22 
strains (Fig. 2), are supposed not to be involved in resistance. 23 
 RpoB sequence comparisons revealed that most changes not involved in rifampin 24 
 6 
resistance were conserved among the species (no more than two amino acid differences in 1 
regions I, II and III) (Fig. 2). These changes could be considered as a species-specific 2 
amino acid signature that give information about the phylogenetic origin of the isolates, as 3 
observed for ComC (29). On the basis of similarity scores with type strains (ClustalW), six 4 
groups could be deduced (Fig. 2) coinciding with the six clusters of the phylogenetic tree 5 
based on 16S rDNA-sodA-rpoB-hlpA sequences (Fig. 1). Two exceptions were observed: S. 6 
pseudopneumoniae type strain that shared the same similarity with S. pneumoniae and S. 7 
mitis; and isolate 889 (S. parasanguinis by the concatenated sequence) that shared the same 8 
similarity with S. gordonii and S. sanguinis. Furthermore, this amino acid signature allowed 9 
us to ascertain the origin of recombinant RpoBs. Six rifampin-resistant S. pneumoniae 10 
recombinant isolates, which we had previously characterized (19), were compared with 11 
other VS. Four of them grouped with S. mitis and S. oralis (RIF13, -25, -24, and 56) (Fig. 12 
2). The source for isolates RIF31 and RIF65 could not be deduced because of the partial 13 
recombinational nature of the first (19) and poor scores with any of the type strains for the 14 
last, due to either the donor is not included in this comparison or several recombination 15 
events have occurred. In conclusion, S. pneumoniae and SMG share the same mechanisms 16 
of rifampin resistance and recombination events in S. pneumoniae take place mostly with S. 17 
mitis and S. oralis species.  18 
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FIGURE LEGENDS 4 
 5 
FIG. 1. Phylogenetic tree of concatenated sequences of 16S rDNA, sodA, rpoB, and hlpA. 6 
Analysis was conducted with the MEGA program (version 4.0.2) with the Neighbor Joining 7 
algorithm. Bootstrap confidence intervals exceeding 90% are shown in italics. The scale bar 8 
calculated by the MEGA program indicates the genetic divergence. Eight S. pyogenes 9 
strains were used as outgroup. Shadowed in grey are clusters that identified S. pneumoniae 10 
(Spn) plus S. pseudopneumoniae (Sps); S. mitis (Smi); S. oralis (Sor); S. parasanguinis 11 
(Spa); S. sanguinis (Ssa) and S. gordonii (Sgo); S. anginosus (San); and S. pyogenes (Spy) 12 
strains. SMG isolates characterized in this work appear in boldface and followed by an 13 
asterisk. The arrow indicates the node that separates S. pneumoniae plus S. 14 
pseudopneumoniae from the rest of the clusters.  15 
FIG. 2. Amino acid sequence variations in RpoB (V475- A702) of rifampin-resistant 16 
recombinant isolates of S. pneumoniae (Spn-M) and SMG rifampin-resistant isolates 17 
characterized in this work (boldface and marked with an asterisk). RpoB is represented as a 18 
bar with clusters N, I, II, and III as black boxes and zigzagged areas showing sequenced 19 
areas. The amino acids present at each polymorphic site are shown in full for S. 20 
pneumoniae strains (R6, P1031, Hungary, Taiwan1, TIGR4, and JJA). For the other strains 21 
only sites that differ from those are shown. Residue numbers are indicated vertically above 22 
the sequences and black boxes below numbers localize clusters I and III. Amino acid 23 
changes involved in rifampin resistance are shown in boldface and underlined. Species 24 
nomenclature as in Fig. 1. 
T
 indicates type strain. Recombinant sequences are shadowed in 25 
 14 
grey. Squares group sequences with highest similarity according to scores obtained by 1 
ClustalW alignments.  2 
 15 













60 DB  PEN, ERY, RIF S. sanguinis S. parasanguinis (98.6) 
79 AF ERY, CLI, SXT, 
RIF 
S. sanguinis S. oralis (97.6)  
113 WS PEN, RIF S. oralis S. oralis (98.1)  
395 AF RIF S. sanguinis S. gordonii (98.9) 
745 AF ERY, CLI, TET, 
SXT, RIF 
S. sanguinis S. oralis (98.4) 
779 BL RIF S. mitis S. mitis (98.7) 
889 B PEN, SXT, RIF S. parasanguinis S. parasanguinis (97.4) 




DB, duodenal biopsy; AF, ascitic fluid; WS, wound swab; BL, bronchoalveolar lavage; B, 3 
blood; E, eye. 4 
b
 PEN, intermediate or high resistant to penicillin (MIC ≥ 0.25 µg/ml); TET, resistant to 5 
tetracycline (MIC ≥8 µg/ml); ERY, resistant to erythromycin (MIC ≥1 µg/ml); CLI, 6 
resistant to clindamycin (MIC ≥1 µg/ml); SXT, resistant to trimethropin-sulfamethoxazole 7 
(MICs, ≥4/76 µg/ml); RIF, resistant to Rifampin (MIC ≥4 µg/ml). 8 
c
 The species identification was based on clustering with type strains in a phylogenetic tree 9 
obtained with a concatenated of partial sequences of 16S rDNA, sodA, rpoB and hlpA. 10 














































































































































RESIDUE 4444445555555555666666666666666666677  Rifampin
7888990667789999000001122222677899900  MIC
5689594081390479013784602347914315602  (µg/ml)
Spn strains VQMDSHSVDTVYTARNEDTKIQVYANIYNQYAVYDTA  0.015
Spn-M RIF31      ...V.......F.........................  512
SpsT CCUG4955 ....................V.....V..........  0.015
SmiT NCTC12261 ...........F........V.....V..K.......  0.015
Smi 779* .....Y.....F........V.....V..K.......  128
Spn-M RIF25       .....N.....F........V.....V..K.......  8
Spn-M RIF13      .....N.....F........V.....V.DK.......  16
SorT NCTC11427 ...........F........V....EV.DK.......  0.015
Sor 745* .....N.....F........V....EV.DK.......  32
Sor 113* .L.........F........V....EV.DK.......  32
Sor 79* ....F.....AF........T....EV.DK...H...  32
Spn-M RIF24       .....N.....F........V....EV.DK.V.....  64
Spn-M RIF56       .....N.....F........V....EV.DK.V.....  64
SpaT NCTC12854 I......I.K..I.K..EGP.RNFSDQ.DK.......  0.03
Spa 60* I....Y.I.K..I.K..EGP.RNFSDQ.DK.......  64
Spa 971* I....N.I.K..ISK..KGP.RNFSDQ.DK...H...  32
SsaT SK36 I......I.K.FI.K..KGP..NFSDQ.DK...H...  0.06
Spa 889* I..V...I.K.FI.K..EGP..NFSDQ.DK...H...  128
SgoT NCTC7868 I......I.A.FI.K..EGP..NFSDQ.DK...H...  0.125
Sgo 395* I.....FI.A.FI.K..EGP..NFSDQ.DK...H...  128
SanT ATCC33397 I......I..LFI.KT..RA..NFSDQFDK..IH.VS  0.125
San 113A I.I..Y.IN.LFI.K...RA..NFSDQFDH...H.VS  256
Spn-M RIF65      .....N.IAK....K.A...V...SS..DKF.I....  16
1200
N I II
200 400 600 800 1000
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I III
